Department Metrics

• 2/2 Ponce Health Sciences University-Moffitt Cancer Center Partnership
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,PI (MPI):Monteiro, A.,Project PI:Peres, L.
• High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
  Award Number:
  Sponsor: US Army
  PI:Pilon-Thomas, S.
• Heterogeneity of metastatic small cell lung cancer; implications for the design of effective immunotherapies
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI (Contact):Beg, A.,PI (MPI):Haura, E.
• Tissue-Anchored vs. Circulating Constructs for Immunometabolic Resolution of Psoriasis
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Targeting dendritic cells to improve cancer immunotherapy
  Award Number:
  Sponsor: Cancer Research Institute
  PI:Ruffell, B.
• CD3z-Independent Signaling Module for CAR-T Cell Therapies Against Solid Cancer
  Award Number:
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Guevara, J.
• Defining Impact of in SITU Activation of CD40 and Type 1 Interferon Signaling on theTME and Systemic T Cell Immunity in Murine models and cancer patients
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Beg, A.
• Impact and Utilization of Scalable Functional Assays in Alagille Syndrome
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Luca, V.
• Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (MPI):Pilon-Thomas, S.
• Moffitt ACS Post-Baccalaureate Diversity in Cancer Research (MAP-DICR)
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• ENCOURAGE Diversity
  Award Number:
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• IMPACT OF TREM2 ON GASTRIC CANCER
  Award Number:
  Sponsor: Amer Gastroenterological Assoc.
  PI:Molgora, M.
• Cancer screening behaviors among people with and without HIV in All of Us
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,Project PI:Islam, J.

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib with or without Imlunestrant in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases (STRONG Trial)
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); Imlunestrant (); LY2835219 (Abemaciclib); Radiotherapy ()

CLINICAL TRIAL 21341
A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Ziv-aflibercept ()

CLINICAL TRIAL 21676
Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan with Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer with Brain Metastases (TARGET-TNBC)
Condition: Breast
Intervention: Sacituzumab Govitecan (); Zimberelimab ()

CLINICAL TRIAL 21757
Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer
Condition: Breast
Intervention: Radiotherapy ()

CLINICAL TRIAL 21955
Phase 2 Study of Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lymphoma after Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Tafasitamab ()

CLINICAL TRIAL 22080
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Condition: Malignant Hematology
Intervention: Adriamycin (doxorubicin); Axicabtagene Ciloleucel (Yescarta); Etoposide (); Rituxan (rituximab); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); fludarabine (Fludarabine phosphate); prednisone (); rituximab ()

CLINICAL TRIAL 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()

CLINICAL TRIAL 22367
The Impact Of Inflammation On HSPC Composition And Disease Progression In Chronic Myelomonocytic Leukemia (CMML INTERCEPT STUDY) SUB-TITLE: Intercepting CMML Disease Progression Driven by Acute Inflammation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22574
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Relatlimab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 23184
Immunoglobulin Replacement Therapy and Infectious Complications After CD19-Targeted CAR-T-Cell Therapy (CARIsMA)
Condition: Malignant Hematology
Intervention: Placebo ()

CLINICAL TRIAL 23240
A Phase 1, Open Label Single-Arm Two-Part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy Of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subjects with Solid Tumors Harboring Genetic Alterations in the MAPK Pathway And With Other Solid Tumors
Condition: Cutaneous
Intervention: NST-628 ()

CLINICAL TRIAL 23320
A Phase 2, Open-label, Multicenter Study of MB-105 in Patients with CD5 Positive (CD5+) Relapsed/Refractory T-cell Lymphoma (r/r TCL)
Condition: Malignant Hematology
Intervention: MB-105 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23363
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3)
Condition: Malignant Hematology
Intervention: ALLO-647 (); Cema-cel (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23433
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer following Neoadjuvant Chemotherapy and Surgery
Condition: Breast
Intervention:

CLINICAL TRIAL 23475
A Phase 1/2 Study of OR502 Alone and in Combination with other Anti-cancer Agents in Subjects with Advanced Malignancies
Condition: Cutaneous
Intervention: Cemiplimab (); OR502 (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 23548
A Phase 1, Open-Label, Dose Escalation and Expansion Study of STX-0712 in Patients with Advanced Hematologic Malignancies
Condition: Malignant Hematology
Intervention: STX-0712 ()

CLINICAL TRIAL 23598
A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Condition: Genitourinary
Intervention: Sacituzumab tirumotecan ()

CLINICAL TRIAL 23706
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (Yescarta)

CLINICAL TRIAL 24030
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
Condition: Breast
Intervention:

• Chaudhary R, Moorhead G, Park R, Li J, Schell MJ, Song X, Tan A, Slebos RJC, Biernacki MI, Freeman SS, Thatikonda S, Meshkovska Y, Hernandez-Prera J, Kirtane K, Guevara-Patino JA, Amelio AL, Rocco JW, Danysh BP, Bonomi M, Saba NF, Haradhvala NJ, Getz G, Chung CH. Long-term Survival and Molecular Biomarker Evaluation of a Phase II Cetuximab and Nivolumab Clinical Trial in Recurrent/Metastatic Head and Neck Cancer. Clin Cancer Res. 2026 Feb.32(3):501-515. Pubmedid: 41117857. Pmcid: PMC12667737.
• Du S, Nguyen KM, Ulezko Antonova A, Fachi JL, Rodrigues PF, Verdiani A, Molgora M, Smirnov I, Herz J, Mamuladze T, Ponce J, Swain A, Bugatti M, Gilfillan S, Cella M, Vermi W, Kipnis J, Colonna M, Brioschi S. Publisher Correction: Diversity and immune dynamics of choroid plexus macrophages are shaped by distinct developmental origins. Nat Neurosci. 2026 Feb. Pubmedid: 41644654.
• Bryant JM, Shotbolt M, Stimphil E, Andre V, Zhang E, Estrella V, Husain K, Weygand J, Marchion D, Lopez AS, Abrahams D, Chen S, Abdel-Mottaleb M, Conlan S, Oraiqat I, Khatri V, Guevara JA, Pilon-Thomas S, Redler G, Latifi K, Raghunand N, Yamoah K, Hoffe S, Costello J, Frakes JM, Liang P, Gatenby RA, Malafa M, Khizroev S. Magnetoelectric Nanotherapy Achieves Complete Tumor Ablation and Prolonged Survival in Pancreatic Cancer Murine Models. Adv Sci (Weinh). 2026 Feb.13(9):e17228. Pubmedid: 41178530. Pmcid: PMC12904064.
• Philbrook P, Dean MJ, Sanchez-Pino MD, Zheng LQ, Zabaleta J, Vázquez-Martínez JA, Chang D, Mandula JK, Shaw TI, Wyczechowska D, Garai J, Thylur Puttalingaiah R, Mansouri A, Huang W, Das S, Chang S, Conejo-Garcia JR, Rodriguez PC, Ochoa AC. Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T cells Antitumor Immunity Through Metabolic Reprogramming. Cancer Immunol Res. 2026 Jan. Pubmedid: 41557755.
• Du S, Nguyen KM, Ulezko Antonova A, Fachi JL, Rodrigues PF, Verdiani A, Molgora M, Smirnov I, Herz J, Mamuladze T, Ponce J, Swain A, Bugatti M, Gilfillan S, Cella M, Vermi W, Kipnis J, Colonna M, Brioschi S. Diversity and immune dynamics of choroid plexus macrophages are shaped by distinct developmental origins. Nat Neurosci. 2026 Jan. Pubmedid: 41566006.
• Ming Q, Luca VC. A little "BiTS" of LAG3 agonism, a big effect on T-cell autoimmunity. Immunol Cell Biol. 2026 Jan.104(1):4-6. Pubmedid: 41177146.
• Horta M, Augusto BM, Wright KL, Jacobsen P, Gonzalez B, Brandon TH, Vadaparampil ST, Simmons VN. 20 Years in the Making: Advancing Postdoctoral Training in Translational Behavioral Oncology. J Cancer Educ. 2025 Dec. Pubmedid: 41350962.
• Di Meo F, Albano F, Cesarano A, Wang Y, Kale B, Shain K, Silva A, Kurihara N, Tenshin H, Jellyman D, Song X, Ghaffari S, Mesa H, Creelan B, Freeman C, Zhao X, Meads MB, Rodriguez PC, Marino S, Locke F, Hwu P, Roodman D, Mansilla-Soto J, Perna F. Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. Cancer Cell. 2025 Dec.43(12):2298-2310.e6. Pubmedid: 41072416. Pmcid: PMC12614569.
• Prabhakaran S, Gatenbee CD, Robertson-Tessi M, Gahramanli Ozturk Z, Boyle TA, Gray JE, Antonia SJ, Gatenby RA, Beg AA, Anderson ARA. Distinct Tumor-Immune Ecologies in Lung Cancer Patients Predict Progression and Define a Clinical Biomarker of Therapy Response. Cancer Res. 2025 Dec. Pubmedid: 41418101. Pmcid: PMC12871056.
• Karapetyan L, Kuriakose J, DiMaggio E, Ward K, Chau J, Otteni C, Kalos D, Ali J, Hall MS, Beatty M, Klinkova OV, Alomar ME, Gaskill EE, Gonzalez RM, Bailey H, Yu M, Tran N, Rodriguez-Alfonso L, Vieira E, Adams K, Jain M, Locke FL, Baldonado J, Perez MC, Mullinax J, Zager JS, Gonzalez R, Sondak VK, Markowitz J, Brohl AS, Eroglu Z, Tarhini AA, Khushalani NI, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients. Transplant Cell Ther. 2025 Dec. Pubmedid: 41421538.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. The Myeloid Biomarker MS4A6A Drives an Immunosuppressive Microenvironment in Glioblastoma via Activation of the PGE2 Signaling Axis. Int J Mol Sci. 2025 Dec.27(1). Pubmedid: 41515934. Pmcid: PMC12785608.
• Smalley TB, Nicolaci AA, Tran KC, Lokhandwala J, Obertopp N, Matlack JK, Miner RE, Teng MN, Pilon-Thomas S, Binning JM. Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer. Mol Ther. 2025 Nov.33(11):5415-5426. Pubmedid: 40873032. Pmcid: PMC12582245.
• Thatikonda S, Chaudhary R, Meshkovska Y, Biernacki M, Slebos RJC, Song X, Hall MS, Lilley K, Pilon-Thomas S, Guevara-Patino JA, Spiess PE, Chahoud J, Amelio AL, Wachter EA, Rodrigues D, Chung CH. PV-10 Triggers Immunogenic Cell Death in Head and Neck Squamous Cell Carcinoma via Endoplasmic Reticulum Stress and Apoptosis. Mol Cancer Ther. 2025 Nov.24(11):1733-1748. Pubmedid: 40552938. Pmcid: PMC12327362.
• Obertopp N, Bekker RA, Grass GD, Zelenka T, Thomas A, Potez M, Ali J, Blauvelt J, Hall AM, Hall MS, Chung CH, Enderling H, Pilon-Thomas S. Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes. Int J Radiat Oncol Biol Phys. 2025 Nov.123(4):1102-1115. Pubmedid: 40582598.
• Wang X, Li T, Eljilany I, Soupir A, Radmacher M, Agius P, Sukrithan V, Ratan A, McCarter M, Salhia B, Colman H, Naqash AR, Puzanov I, Arnold S, Marin-Acevedo JA, Ganesan S, Churchman M, Hwu P, Rodriguez PC, Dalton WS, Weiner GJ, Tarhini AA. Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors. Nat Commun. 2025 Nov.16(1):9968. Pubmedid: 41233329. Pmcid: PMC12615696.
• Karapetyan L, Kuriakose J, Perez MC, Ali JR, Hall MS, Beatty MS, Otteni CD, Xu J, Kalos D, Moran-Segura C, Vieira E, Adams K, Rodriguez-Alfonso L, DiMaggio EC, Bailey H, Pinilla-Ibarz J, Locke FL, Mullinax JE, Chen PL, Song J, Messina JL, Johnson DB, Morgan DS, Eroglu Z, Khushalani NI, Sondak VK, Sarnaik AA, Tsai K, Mulé JJ, Pilon-Thomas S. Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. Front Immunol. 2025 Nov.16:1718443. Pubmedid: 41333460. Pmcid: PMC12665918.
• Obertopp N, Froid M, Pilon-Thomas S, Basanta D. Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling. bioRxiv. 2025 Nov. Pubmedid: 41332775. Pmcid: PMC12667981.
• Falahat R, Mulé JJ. Chemokine/cytokine-releasing biomaterials induce in situ tertiary lymphoid-like structures and enhance antitumor immunity. Proc Natl Acad Sci U S A. 2025 Nov.122(45):e2409560122. Pubmedid: 41183186. Pmcid: PMC12625823.
• Hänggi K, Ruffell B. Protocol for specific induction of apoptosis or necroptosis in established murine tumors. STAR Protoc. 2025 Nov.6(4):104185. Pubmedid: 41205180.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. RNF135 Expression Marks Chemokine (C-C Motif) Ligand-Enriched Macrophage-Tumor Interactions in the Glioblastoma Microenvironment. Cancers (Basel). 2025 Oct.17(19). Pubmedid: 41097797. Pmcid: PMC12523845.
• Hesterberg RS, Davis JT, Handoo KJ, Elmarsafawi AG, Augello AC, Cheng CH, Atkins R, Lee DH, Yang C, Yao J, Patel KR, Mediavilla-Varela M, Pinilla-Ibarz J, Soto-Palma C, Locke FL, Song X, Wang X, Berglund AE, Rodriguez PC, Knittel G, Flümann R, Reinhardt HC, Shaw TI, Yu X, Niedernhofer LJ, Cleveland JL. Lymphoma accelerates T cell and tissue aging. Cancer Cell. 2025 Oct.43(10):1917-1936.e8. Pubmedid: 40845845.
• Hwang SM, Chang S, Rodriguez PC, Cubillos-Ruiz JR. Endoplasmic reticulum stress responses in anticancer immunity. Nat Rev Cancer. 2025 Sep.25(9):684-702. Pubmedid: 40555746. Pmcid: PMC12486299.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies. Cells. 2025 Sep.14(18). Pubmedid: 41002423. Pmcid: PMC12468907.
• Potez M, Roman Souza G, Spiess PE, Pilon-Thomas S, Chahoud J. The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers. Nat Rev Urol. 2025 Sep. Pubmedid: 41006825.
• Potez M, Jazayeri SB, Guske C, Miller J, Ali J, Carter M, Khambati F, Dhillon J, Sexton W, Zemp L, Manley B, Souza GR, Spiess PE, Beatty M, Pilon-Thomas S, Chahoud J. Feasibility and Functional Reactivity of Expanded Tumor-infiltrating Lymphocytes from Non-clear-cell Renal Cell Carcinoma. Eur Urol. 2025 Sep. Pubmedid: 40962596.
• Perez DH, Antfolk D, Chang S, Bustos XE, Medina E, Ramadan AA, Gonzalez-Perez D, Abate-Daga D, Rodriguez PC, Luca VC. Engineering synthetic agonists for targeted activation of Notch signaling. Nat Chem Biol. 2025 Sep. Pubmedid: 40993428.
• Singh S, Julia E, Kalita P, Mason C, Ming Q, Lee-Sam A, Gordon S, Buitrago ME, Leung DW, Hwu P, Luca VC. Structure-guided engineering of CD112 receptor variants for optimized immunotherapy. Mol Ther. 2025 Aug.33(8):3590-3604. Pubmedid: 40285356. Pmcid: PMC12368799.
• Phadke MS, Li J, Sriramareddy S, Rodriguez PC, Ruffell B, Luca VC, Tran TTT, Chen YA, Smalley KSM. Identification of anti-TIM-3 based checkpoint inhibitor combinations with activity in immunotherapy refractory melanoma models. J Immunother Cancer. 2025 Aug.13(8). Pubmedid: 40825611. Pmcid: PMC12366563.
• Yu X, Jain MD, Menges MA, Cen L, Noble JD, Atkins R, Mohammad TJ, Bachmeier CA, Naderinezhad S, Reid K, Corallo S, Yoder SJ, Zhang C, Zhang L, Miranda JA, Shah B, Chavez JC, Hesterberg RS, Delgado LC, Savid-Frontera C, Rodriguez PC, Cleveland JL, Wang X, Davila ML, Locke FL. Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing. J Immunother Cancer. 2025 Jul.13(7). Pubmedid: 40730421. Pmcid: PMC12306477.
• Feng Y, Yuan Q, Zuniga A, Islam S, Avram D, Guryanova OA. Optimized Mouse Model to Induce Colitis-Associated Colon Cancer using Azoxymethane and Dextran Sulfate Sodium for Tumor Immunology and Therapy Studies. J Vis Exp. 2025 Jul.(221). Pubmedid: 40788861.
• Gallagher K, Sousa RS, Gatenbee C, Schenck R, Chen P, Citak T, Leither S, Mazzacurati L, Xella A, Zhou Z, Lemanne D, Rodriguez P, George E, Strobl MAR. Controlling treatment toxicity in ovarian cancer to prime the patient for tumor extinction therapy. bioRxiv. 2025 Jul. Pubmedid: 40791474. Pmcid: PMC12338546.
• Flaherty KT, Aplin AE, Davies MA, Hacohen N, Herlyn M, Hoon D, Hwu P, Lotem M, Mulé J, Wargo JA, Fisher DE. Facts and Hopes: Toward the Next Quantum Leap in Melanoma. Clin Cancer Res. 2025 Jul.31(14):2882-2889. Pubmedid: 40407722. Pmcid: PMC12240026.
• Antfolk D, Ming Q, Manturova A, Goebel EJ, Thompson TB, Luca VC. Molecular mechanism of Activin receptor inhibition by DLK1. Nat Commun. 2025 Jul.16(1):5976. Pubmedid: 40593645. Pmcid: PMC12216052.
• Ugolini A, De Leo A, Yu X, Scirocchi F, Liu X, Peixoto B, Scocozza D, Pace A, Perego M, Gardini A, D'Angelo L, Liu JKC, Etame AB, Rughetti A, Nuti M, Santoro A, Vogelbaum MA, Conejo-Garcia JR, Rodriguez PC, Veglia F. Functional Reprogramming of Neutrophils within the Brain Tumor Microenvironment by Hypoxia-Driven Histone Lactylation. Cancer Discov. 2025 Jun.15(6):1270-1296. Pubmedid: 40014923. Pmcid: PMC12133432.
• Srivastava J, Yadav VK, Jimenez RV, Phadatare PR, Inamdar NA, Young MM, Bacchiocchi A, Halaban R, Fang B, Pulido AM, Tsai KY, Smalley KSM, Koomen JM, Rodriguez PC, Premi S. Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors. Cancer Res. 2025 Jun.85(12):2268-2287. Pubmedid: 40287947. Pmcid: PMC12167936.
• Mansilla-Soto J, Milone MC. Concept CARs are picking up speed. Mol Ther. 2025 Jun.33(6):2363-2367. Pubmedid: 40340247. Pmcid: PMC12172278.
• Milone MC, Mansilla-Soto J, Pardi N, George LA, Byrne BJ, Herzog RW. Clinical advances in gene, cell, and RNA therapies. Mol Ther. 2025 Jun.33(6):2311. Pubmedid: 40398418. Pmcid: PMC12172262.
• Gao Y, Yin Q, Gamallat Y, Grant MG, Snell AH, Shi X, Ulstad LN, Singh A, Chen T, Johnson JO, Avram D, Wan L. Linear ubiquitination of p31comet by HOIP couples cytokine response with mitotic regulation. Cell Biosci. 2025 Jun.15(1):75. Pubmedid: 40462232. Pmcid: PMC12135451.
• Chamseddine I, Kambara M, Bhatt P, Pilon-Thomas S, Rejniak KA. Optimizing the Efficacy of Vaccine-Induced Immunotherapy in Melanomas. Bull Math Biol. 2025 May.87(7):86. Pubmedid: 40434675. Pmcid: PMC12279038.
• Chen J, Wu Q, Berglund AE, Macaulay RJ, Mulé JJ, Etame AB. Identification of an Immune-Related Gene Signature for Prognostic Prediction in Glioblastoma: Insights from Integrated Bulk and Single-Cell RNA Sequencing. Cancers (Basel). 2025 May.17(11). Pubmedid: 40507280. Pmcid: PMC12153616.
• Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS, Maharaj K, Chavez JC, Powers JJ, Obermayer A, Shaw TI, Conejo-Garcia JR, Rodriguez PC, Sahakian E, Pinilla-Ibarz J, Kater AP. Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. Blood Adv. 2025 May.9(10):2511-2529. Pubmedid: 39938006. Pmcid: PMC12148389.
• Coghill AE, Van Bibber N, Baiocchi RA, Arnold SM, Riedlinger G, Schneider BP, Zhang Y, Suneja G, Gomez Fontela M, Abate-Daga D, Teer JK. Elevated Tumor Mutation Burden in Cancer Patients with Underlying HIV Infection: Data from the Oncology Research Information Exchange Network (ORIEN). Cancer Epidemiol Biomarkers Prev. 2025 May.34(5):774-779. Pubmedid: 40019488. Pmcid: PMC12048233.
• Ramamoorthi G, Lee MC, Farrell CM, Snyder C, Garg SK, Aldrich AL, Lok V, Dominguez-Viqueira W, Olson-Mcpeek SK, Rosa M, Gautam N, Pilon-Thomas S, Cen L, Kodumudi KN, Wiener D, Oskarsson T, Gomes AP, Gatenby RA, Czerniecki BJ. Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells. Cancer Immunol Res. 2025 May.13(5):729-748. Pubmedid: 40249209. Pmcid: PMC12046335.
• Wang C, Yu X, Teer JK, Yao J, Du D, Liu X, Thompson ZJ, Wang MH, Welsh EA, Memon D, Chan TA, Makarov V, Anadon CM, Saeed L, Boyle TA, Fang B, Koomen JM, Cox C, Landin AM, Yoder SJ, Kim S, Chen DT, Pilon-Thomas SA, Conejo-Garcia JR, Antonia SJ, Haura EB, Creelan BC. Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy. Nat Cancer. 2025 May.6(5):801-819. Pubmedid: 40341231.
• Rossetti RAM, Tordesillas L, Beatty MS, Cianne J, Martinez Planes E, Du D, Snedal S, Wang C, Perez BA, Berglund A, Chen YA, Sarnaik A, Mulé JJ, Creelan B, Pilon-Thomas S, Abate-Daga D. CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion. J Immunother Cancer. 2025 Apr.13(4). Pubmedid: 40199608. Pmcid: PMC11979601.
• Takahashi H, Perez-Villarroel P, Falahat R, Mulé JJ. Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming. J Immunother Cancer. 2025 Mar.13(3). Pubmedid: 40081947. Pmcid: PMC11907082.
• Davila M, Lee SB, Kang YP, Boucher J, Mandula J, Roselli E, Chang D, Jimenez R, Kotani H, Reid K, Vazquez-Martinez J, Beatty N, Goala P, Sierra-Mondragon R, Liu M, Koomen J, Nguyen J, Hussaini M, Shaw T, Wang X, Faramand R, Jain M, Locke F, Rodriguez P, Sailer C, McSain S, Hamid S, Tariq M, Wang J, Abraham-Miranda J. CAR T cell-driven induction of iNOS in tumor-associated macrophages promotes CAR T cell resistance in B cell lymphoma. Res Sq. 2025 Mar. Pubmedid: 40235478. Pmcid: PMC11998770.
• Senent Y, Remírez A, Repáraz D, Llopiz D, Celias DP, Sainz C, Entrialgo-Cadierno R, Suarez L, Rouzaut A, Alignani D, Tavira B, Lambris JD, Woodruff TM, de Andrea CE, Ruffell B, Sarobe P, Ajona D, Pio R. The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response. Cancer Immunol Res. 2025 Mar.13(3):384-399. Pubmedid: 39666368.
• Berglund AE, Puskas J, Yoder SJ, Smith AT, Marchion DC, Qin D, Mulé JJ, Torres-Roca JF, Eschrich SA. Evaluating the Radiation Sensitivity Index and 12-Chemokine Gene Expression Signature for Clinical Use in a CLIA Laboratory. Cancer Res Commun. 2025 Mar.5(3):389-397. Pubmedid: 39932296. Pmcid: PMC11873780.
• Luca VC. LAG Time in the Era of Immunotherapy-New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene-3. Immunol Rev. 2025 Mar.330(1):e70002. Pubmedid: 39887765. Pmcid: PMC11917464.
• Wang X, Li T, Slebos RJC, Chaudhary R, Guevara-Patino JA, Bonomi M, Saba NF, Chung CH. Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Cancer Immunol Immun. 2025 Mar.74(4):142. Pubmedid: 40056190. Pmcid: PMC11890688.
• Molgora M, Colonna M. Targeting brain macrophages: NF-κB as a therapeutic gateway in melanoma brain metastasis. Cancer Cell. 2025 Mar.43(3):328-329. Pubmedid: 40068588.
• Nagy MZ, Plaza-Rojas LB, Boucher JC, Kostenko E, Austin AL, Tarhini AA, Chen Z, Du D, Ojwang' AME, Davis J, Obermayer A, Rejniak KA, Shaw TI, Guevara-Patino JA. Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients. J Immunother Cancer. 2025 Feb.13(2). Pubmedid: 40010774.